tiprankstipranks
Trending News
More News >
Tempus AI, Inc. Class A (TEM)
NASDAQ:TEM
US Market
Advertisement

Tempus AI, Inc. Class A (TEM) AI Stock Analysis

Compare
4,059 Followers

Top Page

TE

Tempus AI, Inc. Class A

(NASDAQ:TEM)

Rating:47Neutral
Price Target:
$58.00
▼(-0.02%Downside)
Tempus AI's overall score reflects significant financial challenges, including high leverage and negative profitability. Technical indicators show bearish trends, and the valuation highlights unprofitability. Despite these risks, there is optimism from the earnings call due to revenue growth and strategic partnerships, contributing positively to the score.
Positive Factors
Revenue Growth
Overall core 'Genomics' revenue grew 27% year-over-year, led by higher average selling prices.
Strategic Agreements
Shares of TEM are up +16% on news that the company signed a $200 million expanded strategic agreement with AstraZeneca and Pathos AI.
Negative Factors
Cash Flow
Quarterly cash flow from operations was roughly -$106 million, largely due to timing of cash flows and 'one-timers' with Ambry.
Revenue Estimates
Total revenue fell short of estimates by roughly 2% on the data and services side.

Tempus AI, Inc. Class A (TEM) vs. SPDR S&P 500 ETF (SPY)

Tempus AI, Inc. Class A Business Overview & Revenue Model

Company DescriptionTempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
How the Company Makes MoneyTempus AI, Inc. generates revenue primarily through the sale and licensing of its AI software solutions and platforms. The company offers subscription-based models for its AI services, allowing businesses to access and integrate these technologies into their operations. Additionally, Tempus AI engages in strategic partnerships with other technology firms and industry leaders to co-develop and deploy tailored AI solutions. Consulting and implementation services also contribute to its revenue, as Tempus AI assists clients in customizing and optimizing AI technologies to suit their specific needs. The company may also earn through ongoing support and maintenance contracts, ensuring that clients receive continuous service and updates for their AI systems.

Tempus AI, Inc. Class A Earnings Call Summary

Earnings Call Date:May 06, 2025
(Q1-2025)
|
% Change Since: 11.15%|
Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant year-over-year growth in revenue, gross profit, and genomic segments, alongside improved adjusted EBITDA and strong guidance for future growth. The partnership with AstraZeneca and Pathos is seen as a major achievement. However, challenges remain with a negative adjusted EBITDA and the need to meter MRD volumes due to reimbursement issues.
Q1-2025 Updates
Positive Updates
Record Revenue Growth
Quarterly revenue increased 75.4% year-over-year to $255.7 million.
Genomics Revenue Surge
Genomics revenue was $193.8 million, marking an 89% year-over-year growth.
Oncology and Hereditary Testing Growth
Oncology testing grew 31% year-over-year with approximately 20% volume growth. Hereditary testing revenue was $63.5 million, with units growing by 23%.
Significant Increase in Gross Profit
Quarterly gross profit increased 99.8% year-over-year to $155.2 million.
Improvement in Adjusted EBITDA
Adjusted EBITDA improved by $27.8 million year-over-year, from negative $43.9 million to negative $16.2 million.
Major Partnership with AstraZeneca and Pathos
Announced a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos.
Increased Full Year Revenue Guidance
Full year 2025 revenue guidance increased to $1.25 billion, representing about 80% year-over-year growth.
Negative Updates
Negative Adjusted EBITDA
Despite improvements, adjusted EBITDA remains negative at $16.2 million.
Metered MRD Volume Due to Lack of Reimbursement
Managing and metering volumes for MRD assays due to lack of reimbursement by MolDx.
Company Guidance
During the Tempus First Quarter 2025 Financial Results Conference Call, Eric Lefkofsky, CEO, highlighted a strong start to the year with quarterly revenue growing 75.4% year-over-year to $255.7 million. Genomics revenue saw an 89% increase year-over-year, reaching $193.8 million. Oncology testing grew 31% year-over-year with a 20% increase in volume, while hereditary testing contributed $63.5 million with a 23% growth in units. Revenue from Data and Services totaled $61.9 million, marking a 43% year-over-year increase, with the Insights business growing 58%. Tempus generated $155.2 million in gross profit, reflecting a 99.8% year-over-year growth. The company reported an adjusted EBITDA loss of $16.2 million, an improvement from a $43.9 million loss in Q1 2024. Tempus raised its full-year 2025 revenue guidance to $1.25 billion, representing approximately 80% growth. A significant highlight was a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos, bringing Tempus' total remaining contract value to over $1 billion, which Lefkofsky noted as a milestone toward advancing precision medicine.

Tempus AI, Inc. Class A Financial Statement Overview

Summary
Despite strong revenue growth, Tempus AI, Inc. faces significant financial challenges with persistent losses, high leverage, and negative cash flows, indicating financial instability and potential solvency risks.
Income Statement
45
Neutral
Tempus AI, Inc. has shown impressive revenue growth over the years, with a notable increase from $62.1 million in 2019 to $693.4 million in 2024. However, despite the revenue uptick, the company continues to face significant challenges in managing profitability. The net profit margin remains negative due to persistent losses, and both EBIT and EBITDA margins reflect substantial operating losses. This indicates that while revenue generation is strong, cost management and operational efficiency need significant improvement.
Balance Sheet
30
Negative
The balance sheet reveals a concerning financial structure, with high total liabilities of $869.8 million against a minimal stockholders' equity of $56.3 million in 2024, leading to an unfavorable debt-to-equity ratio. The equity ratio is extremely low, indicating heavy reliance on debt financing. Although the company has managed to maintain a reasonable level of cash and short-term investments, the negative stockholders' equity in recent years signals financial instability and potential solvency risks.
Cash Flow
40
Negative
Operating cash flows are consistently negative, reflecting challenges in generating cash from core operations. Free cash flow has shown volatility, with significant negative figures, indicating that the company is struggling to cover its capital expenditures from its operations. Although there is a positive trend in financing cash flows, suggesting successful capital raising efforts, the heavy reliance on external financing poses a risk if such inflows are not sustainable.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue693.40M531.82M320.67M257.85M188.00M
Gross Profit381.11M286.18M121.68M77.39M22.83M
EBITDA-610.42M-133.33M-236.85M-219.52M-169.37M
Net Income-705.81M-214.12M-289.81M-259.19M-209.85M
Balance Sheet
Total Assets926.12M564.05M631.36M531.35M751.92M
Cash, Cash Equivalents and Short-Term Investments448.26M197.57M302.94M277.69M513.44M
Total Debt468.09M488.14M433.03M238.95M251.45M
Total Liabilities869.78M1.95B734.25M440.55M405.75M
Stockholders Equity56.34M-1.38B-102.88M90.80M346.17M
Cash Flow
Free Cash Flow-211.17M-248.95M-186.58M-223.75M-219.98M
Operating Cash Flow-189.04M-214.34M-168.20M-211.98M-206.56M
Investing Cash Flow-130.39M-40.31M-57.94M-21.72M-13.42M
Financing Cash Flow494.33M117.55M251.39M-2.04M506.11M

Tempus AI, Inc. Class A Technical Analysis

Technical Analysis Sentiment
Negative
Last Price58.01
Price Trends
50DMA
62.92
Negative
100DMA
55.95
Positive
200DMA
53.91
Positive
Market Momentum
MACD
-1.30
Positive
RSI
44.23
Neutral
STOCH
59.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TEM, the sentiment is Negative. The current price of 58.01 is below the 20-day moving average (MA) of 61.11, below the 50-day MA of 62.92, and above the 200-day MA of 53.91, indicating a neutral trend. The MACD of -1.30 indicates Positive momentum. The RSI at 44.23 is Neutral, neither overbought nor oversold. The STOCH value of 59.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TEM.

Tempus AI, Inc. Class A Risk Analysis

Tempus AI, Inc. Class A disclosed 97 risk factors in its most recent earnings report. Tempus AI, Inc. Class A reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Tempus AI, Inc. Class A Peers Comparison

Overall Rating
UnderperformOutperform
Sector (57)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
$10.47B115.862.67%5.46%3.31%-72.63%
64
Neutral
$18.97B-18.66%51.50%53.23%
GHGH
57
Neutral
$5.76B-4584.47%28.20%13.87%
57
Neutral
$5.91B21.40-28.61%4.91%10.78%-34.04%
55
Neutral
$15.22B-23.82%-3.47%25.55%
54
Neutral
$9.52B-36.89%11.57%-315.25%
TETEM
47
Neutral
$10.56B-1252.79%42.93%-160.27%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TEM
Tempus AI, Inc. Class A
58.01
15.03
34.97%
EXAS
Exact Sciences
48.36
0.20
0.42%
ILMN
Illumina
94.80
-22.81
-19.39%
QGEN
Qiagen
48.06
5.95
14.13%
NTRA
Natera
140.63
35.12
33.29%
GH
Guardant Health
45.64
13.64
42.63%

Tempus AI, Inc. Class A Corporate Events

Private Placements and Financing
Tempus AI Announces $400 Million Convertible Notes Offering
Neutral
Jul 3, 2025

On June 30, 2025, Tempus AI, Inc. announced a proposed offering of $400 million in Convertible Senior Notes due in 2030, with an option for an additional $60 million. The proceeds are intended to repay outstanding term loans, reduce interest expenses, and support general corporate purposes, including strategic investments. The offering aims to optimize Tempus’s capital structure and enhance financial flexibility, potentially impacting the market price of its Class A common stock and the conversion price of the Notes.

The most recent analyst rating on (TEM) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Tempus AI, Inc. Class A stock, see the TEM Stock Forecast page.

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Tempus AI Approves Reincorporation and Elects Directors
Neutral
May 23, 2025

Tempus AI, Inc. held its 2025 Annual Meeting of Stockholders on May 20, 2025, where key decisions were made regarding the company’s governance and operational structure. During the meeting, stockholders elected nine directors to serve until the 2026 Annual Meeting, ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025, and approved the reincorporation of the company from Delaware to Nevada. These decisions reflect strategic moves to potentially enhance the company’s governance and operational flexibility.

The most recent analyst rating on (TEM) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Tempus AI, Inc. Class A stock, see the TEM Stock Forecast page.

M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
Tempus AI Reports Strong Q1 2025 Financial Results
Positive
May 6, 2025

On May 6, 2025, Tempus AI, Inc. reported its financial results for the first quarter of 2025, showcasing a 75.4% increase in revenue year-over-year to $255.7 million and a 99.8% rise in gross profit. The company announced strategic collaborations with AstraZeneca and Pathos to develop a multimodal foundation model in oncology, projected to bring in $200 million over the next three years. Tempus also completed the acquisition of Ambry Genetics and disclosed a collaboration with Illumina to enhance genomic algorithms. Despite reporting a net loss of $68 million, Tempus improved its adjusted EBITDA significantly compared to the previous year and increased its full-year revenue guidance to $1.25 billion, representing an 80% growth year-over-year.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 17, 2025